The cardiac myosin inhibitor aficamten (Cytokinetics) is associated with improvements in self-reported health status in patients with obstructive hypertrophic cardiomyopathy (OHCM), according to new ...
Aficamten (Cytokinetics), a novel cardiac myosin inhibitor, safely reduces left ventricular outflow tract (LVOT) gradients and relieves heart failure symptoms in patients with obstructive hypertrophic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results